Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial

Genitourinary CancerSkin Cancer

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

J Clin Oncol.

Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, Voss MH, Sharma P, Pal SK, Razak ARA, Kollmannsberger C, Heng DYC, Spratlin J, McHenry MB, Amin A

doi: 10.1200/JCO.2016.72.1985.

Skin Cancer

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Eur J Cancer.

Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C

doi: 10.1016/j.ejca.2017.05.038.

SPECIAL REPORT

Genitourinary CancerLung, Respiratory and Thoracic CancerSkin Cancer

Meet the Expert

doi: 10.1056/NEJMoa1504627 (2015).

Skin Cancer

Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report

Surg Case Rep.

Yasuda K, Tanaka T, Ishihara S, Otani K, Nishikawa T, Kiyomatsu T, Kawai K, Hata K, Nozawa H, Masui Y, Shintani Y, Watanabe T

doi: 10.1186/s40792-017-0370-7.

Skin Cancer

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

J Clin Oncol.

Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J

doi: 10.1200/JCO.2016.71.8023.

Skin Cancer

Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma

Melanoma Res.

Yip RHL, Lee LH, Schaeffer DF, Horst BA, Yang HM

doi: 10.1097/CMR.

Skin CancerLymphoma

Cystic metastatic lymph nodes in malignant melanoma: a case report

Clin Imaging.

Mema E, Cho E, Ha R, Taback B

doi: 10.1016/

Skin Cancer

Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma

Clin Kidney J.

Murakami N, Borges TJ, Yamashita M, Riella LV

doi: 10.1093/ckj/sfw024.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Ipilimumab/Nivolumab-related Opsoclonus-Myoclonus-Ataxia Syndrome Variant in a Patient with Malignant Pleural Mesothelioma

J Immunother.

Maller B, Peguero E, Tanvetyanon T

doi: 10.1097/CJI.

Related content

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Meet the Expert

Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma

Cystic metastatic lymph nodes in malignant melanoma: a case report

Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma

Ipilimumab/Nivolumab-related Opsoclonus-Myoclonus-Ataxia Syndrome Variant in a Patient with Malignant Pleural Mesothelioma